LONG‐TERM RESPONSES WITH LONCASTUXIMAB TESIRINE: UPDATED RESULTS FROM LOTIS‐2, THE PIVOTAL PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA.

Autor:	Caimi, P. F, Ai, W. Z, Alderuccio, J. P., Ardeshna, K. M, Hamadani, M., Hess, B., Kahl, B. S, Radford, J., Solh, M., Stathis, A., Zinzani, P. L., Wang, Y., Qin, Y., Wang, L., Xu, C., Carlo‐Stella, C.
Předmět:	DIFFUSE large B-cell lymphomas STEM cell transplantation CHIMERIC antigen receptors
Zdroj:	Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p209-212, 4p
Abstrakt:	B Introduction: b Patients (pts) with diffuse large B-cell lymphoma (DLBCL) who relapse after stem cell transplant or chimeric antigen receptor therapy or are refractory to second-line therapy have poor prognosis and few treatment options (Chow et al., 2019). LONG-TERM RESPONSES WITH LONCASTUXIMAB TESIRINE: UPDATED RESULTS FROM LOTIS-2, THE PIVOTAL PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA Stock ownership: ADC Therapeutics Research funding: ADC Therapeutics B L. Wang b Employment or leadership position: ADC Therapeutics. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text